Fel'dblium I V, Nikolaeva A M, Kuz'ianin A V, Borisova V N, Mel'nikov V A, Chuprinina R P, Perelygina O V, Shalunova N V, Semenova V D, Griaznova D V, Pushkareva E V, Uvitskiĭ A Iu, Alekseeva I A, Konopleva O A, Budanov M V, Iakovleva I M
Zh Mikrobiol Epidemiol Immunobiol. 2004 Sep-Oct(5):58-62.
Combined vaccine "Bubo-Kok" is characterized by safety and high immunological activity. The number of postvaccinal reactions in children aged 1 and 2 years, immunized with vaccine "Bubo-Kok", was not statistically different from those in groups of children immunized with adsorbed DPT vaccine, as well with such vaccine in combination with vaccine against hepatitis B. After the completion of the primary course of immunization 100% of children had protective antibody titers against diphtheria, tetanus and hepatitis B. Antibody titers against pertussis, equal to or exceeding protective titers, were found in more than 70% of immunized children. The immunogenic potency of vaccine "Bubo-Kok" with respect to all its components was not inferior to that of adsorbed DPT vaccine and vaccine against hepatitis B, when introduced simultaneously in different areas of the body. Vaccine "Bubo-Kok" successfully passed state trials and was recommended for registration.
联合疫苗“Bubo-Kok”具有安全性和高免疫活性的特点。1岁和2岁儿童接种“Bubo-Kok”疫苗后的疫苗接种后反应数量,与接种吸附百白破疫苗的儿童组以及与乙肝疫苗联合接种的儿童组相比,在统计学上没有差异。完成基础免疫疗程后,100%的儿童对白喉、破伤风和乙肝产生了保护性抗体滴度。在超过70%的接种儿童中发现了针对百日咳的抗体滴度,等于或超过保护性滴度。当同时在身体不同部位接种时,“Bubo-Kok”疫苗在所有成分方面的免疫原性效力不低于吸附百白破疫苗和乙肝疫苗。“Bubo-Kok”疫苗成功通过了国家试验,并被推荐进行注册。